Ku et al. reported that in prostate cancer with PTEN and RB1 deletions and PTEN, RB1, and TP53 deletions, catalytic inhibition of EZH2 can reactivate AR signaling, causing tumors to resensitize to Enz, while also reducing the expression of NEPC target genes. This evidence concerns the gene RB1 and prostate carcinoma.